International AIDS Vaccine Initiative (IAVI) and Merck & Co. scientists have developed a SARS-CoV-2 vaccine using the vesicular stomatitis virus (VSV) chimeric virus approach, wherein VSV was modified by substituting the VSV G surface glycoprotein gene with a coding sequence for the SARS-CoV-2 spike (S) glycoprotein.
Researchers from University of Miami Miller School of Medicine reported preclinical data for ZyVersa Therapeutics' novel humanized IgG4 monoclonal antibody targeting apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), named IC-100.
A first-of-its-kind comprehensive map of the network of connections in the human immune system has uncovered previously unknown interactions and filled in gaps in understanding why approved immunotherapies work in some patients and not others.
Scientists from the University of Washington and the Fred Hutchinson Cancer Research Center and their collaborators have described the generation of self-assembling nanoparticles displaying the Epstein-Barr virus (EBV) gH/gL glycoprotein complex as potential EBV vaccines.
Many pathogens such as HIV, SARS-CoV-2, or those linked to influenza or cholera infect the host through mucosal surfaces and thus are thought to require both systemic and mucosal immune responses for effective management and protection.
An effective universal vaccine ideally providing broad protection against all influenza A virus (IAV) subtypes with pandemic or zoonotic potential circulating in animals, as well as against antigenically variable seasonal strains, remains an urgent public health need.
RSS